Clinical Trial Update: A Tolerability and Pharmacokinetics Study of SHR6390 in Advanced Melanoma Patients [Phase 1]

View source ↗

Summary

This document describes a Phase 1 tolerability and pharmacokinetics study of SHR6390 in patients with advanced melanoma. The sponsor is Jiangsu HengRui Medicine…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma

Drugs mentioned

• SHR6390 (SHR6390)

Snippet

Sponsor: Jiangsu HengRui Medicine Co., Ltd. | Conditions: Melanoma | Phase 1 | Status: UNKNOWN